Huvepharma selects HatchTech for vaccine production

Huvepharma, one of the largest animal health companies in the world, has partnered with HatchTech on an innovative long-term vaccine hatchery project.

Huvepharma’s line of products delivers innovative solutions for both animal and human health. This latest vaccine project is currently in development and will involve HatchTech MicroClimer Setters. The used embryos/eggs will be used in the production of veterinarian vaccines.

After the comparison between the different solutions present on the market, due to the technical complexity of the project, Huvepharma has turned to HatchTech as a trusted partner.

Embryo harvesting for vaccines

HatchTech’s laminar airflow technology was a deciding factor in the tendering of this contract, given that embryos used in the production of vaccines are much more valuable – and much more vulnerable to contamination – than those of eggs produced for human consumption.

HatchTech’s MicroClimer solution ensures optimal conditions for each embryo in the machine, and helps guarantee that every egg’s potential is reached in supporting vaccine production. MicroClimer Setter trolleys are specifically designed to accommodate the JamesWay tray, which is the storage tray frequently used by vaccine hatcheries around the world.

“I’m proud that our company has again been chosen as a partner by a leading vaccine producer,” says Patrick van Manen, International Sales Manager at HatchTech. “This important contract underlines not only the reliable and predictable performance of our machines, but also their versatility and usability in different contexts. I’m also excited that HatchTech is continuing to make a valuable contribution to the field of vaccine development – which, in the current environment, is more important than ever.”